Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.02
INCY's Cash to Debt is ranked lower than
78% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. INCY: 1.02 )
Ranked among companies with meaningful Cash to Debt only.
INCY' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: 1.24 Max: No Debt
Current: 1.02
Equity to Asset 0.10
INCY's Equity to Asset is ranked lower than
91% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. INCY: 0.10 )
Ranked among companies with meaningful Equity to Asset only.
INCY' s Equity to Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.07 Max: 0.79
Current: 0.1
-1.83
0.79
F-Score: 5
Z-Score: 7.91
M-Score: -2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -6.32
INCY's Operating margin (%) is ranked higher than
67% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. INCY: -6.32 )
Ranked among companies with meaningful Operating margin (%) only.
INCY' s Operating margin (%) Range Over the Past 10 Years
Min: -4064.53  Med: -199.61 Max: 8.27
Current: -6.32
-4064.53
8.27
Net-margin (%) -13.50
INCY's Net-margin (%) is ranked higher than
64% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. INCY: -13.50 )
Ranked among companies with meaningful Net-margin (%) only.
INCY' s Net-margin (%) Range Over the Past 10 Years
Min: -4565.45  Med: -224.88 Max: -9.48
Current: -13.5
-4565.45
-9.48
ROA (%) -9.86
INCY's ROA (%) is ranked higher than
66% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. INCY: -9.86 )
Ranked among companies with meaningful ROA (%) only.
INCY' s ROA (%) Range Over the Past 10 Years
Min: -70.43  Med: -21.76 Max: -5.3
Current: -9.86
-70.43
-5.3
ROC (Joel Greenblatt) (%) -45.86
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. INCY: -45.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INCY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4727.38  Med: -658.62 Max: 38.66
Current: -45.86
-4727.38
38.66
Revenue Growth (3Y)(%) 59.60
INCY's Revenue Growth (3Y)(%) is ranked higher than
94% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. INCY: 59.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INCY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.4  Med: 15.95 Max: 194.1
Current: 59.6
-61.4
194.1
EPS Growth (3Y)(%) -42.10
INCY's EPS Growth (3Y)(%) is ranked lower than
89% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. INCY: -42.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INCY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -45  Med: -8.75 Max: 64.9
Current: -42.1
-45
64.9
» INCY's 10-Y Financials

Financials (Next Earnings Date: 2016-02-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

INCY Guru Trades in Q1 2015

Vanguard Health Care Fund 10,174,343 sh (unchged)
Ken Fisher 14,870 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

INCY Guru Trades in Q2 2015

Joel Greenblatt 10,363 sh (New)
Jim Simons 275,000 sh (New)
Vanguard Health Care Fund 9,411,543 sh (-7.50%)
Ken Fisher 13,695 sh (-7.90%)
» More
Q3 2015

INCY Guru Trades in Q3 2015

Paul Tudor Jones 9,555 sh (New)
John Burbank 309,627 sh (New)
Ken Fisher 14,495 sh (+5.84%)
Vanguard Health Care Fund 9,233,028 sh (-1.90%)
Joel Greenblatt 4,861 sh (-53.09%)
Jim Simons 33,200 sh (-87.93%)
» More
Q4 2015

INCY Guru Trades in Q4 2015

Vanguard Health Care Fund 9,615,828 sh (+4.15%)
Ken Fisher 14,818 sh (+2.23%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Incyte Corp

The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Prothena Corp. tops the list with a 148% return year-to-date
Jean M. Hynes has managed the Vanguard Health Care Fund (Trades, Portfolio) (VGHCX) since 2008, which is now composed of 82 stocks. The following are the stocks in the portfolio with the highest performance since the beginning of the year. Read more...

Ratios

vs
industry
vs
history
Forward P/E 44.84
INCY's Forward P/E is ranked lower than
87% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.89 vs. INCY: 44.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 147.92
INCY's P/B is ranked lower than
99.99% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. INCY: 147.92 )
Ranked among companies with meaningful P/B only.
INCY' s P/B Range Over the Past 10 Years
Min: 9.1  Med: 198.00 Max: 386.87
Current: 147.92
9.1
386.87
P/S 19.94
INCY's P/S is ranked lower than
68% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. INCY: 19.94 )
Ranked among companies with meaningful P/S only.
INCY' s P/S Range Over the Past 10 Years
Min: 7.19  Med: 23.56 Max: 209.75
Current: 19.94
7.19
209.75
PFCF 338.10
INCY's PFCF is ranked lower than
94% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.21 vs. INCY: 338.10 )
Ranked among companies with meaningful PFCF only.
INCY' s PFCF Range Over the Past 10 Years
Min: 7.24  Med: 319.81 Max: 941.29
Current: 338.1
7.24
941.29
POCF 208.82
INCY's POCF is ranked lower than
89% of the 383 Companies
in the Global Biotechnology industry.

( Industry Median: 28.02 vs. INCY: 208.82 )
Ranked among companies with meaningful POCF only.
INCY' s POCF Range Over the Past 10 Years
Min: 7.19  Med: 239.49 Max: 732.11
Current: 208.82
7.19
732.11
EV-to-EBIT -352.53
INCY's EV-to-EBIT is ranked lower than
99.99% of the 450 Companies
in the Global Biotechnology industry.

( Industry Median: 20.72 vs. INCY: -352.53 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8542.7  Med: -9.50 Max: 1569.2
Current: -352.53
-8542.7
1569.2
EV-to-EBITDA 1454.64
INCY's EV-to-EBITDA is ranked lower than
99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 18.13 vs. INCY: 1454.64 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -721.9  Med: -7.00 Max: 2618.5
Current: 1454.64
-721.9
2618.5
Current Ratio 4.86
INCY's Current Ratio is ranked higher than
51% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. INCY: 4.86 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.08 Max: 21.14
Current: 4.86
1.51
21.14
Quick Ratio 4.85
INCY's Quick Ratio is ranked higher than
53% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. INCY: 4.85 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.08 Max: 21.14
Current: 4.85
1.51
21.14
Days Inventory 27.79
INCY's Days Inventory is ranked higher than
86% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 124.17 vs. INCY: 27.79 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 46.41  Med: 198.14 Max: 323.15
Current: 27.79
46.41
323.15
Days Sales Outstanding 50.08
INCY's Days Sales Outstanding is ranked higher than
63% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. INCY: 50.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 38.86 Max: 6447.52
Current: 50.08
12.25
6447.52
Days Payable 507.14
INCY's Days Payable is ranked higher than
96% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 57.61 vs. INCY: 507.14 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 2972.25  Med: 11067.03 Max: 32457.1
Current: 507.14
2972.25
32457.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 147.92
INCY's Price/Tangible Book is ranked lower than
99% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. INCY: 147.92 )
Ranked among companies with meaningful Price/Tangible Book only.
INCY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.91  Med: 5.76 Max: 336.16
Current: 147.92
0.91
336.16
Price/Median PS Value 0.84
INCY's Price/Median PS Value is ranked higher than
54% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INCY: 0.84 )
Ranked among companies with meaningful Price/Median PS Value only.
INCY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 0.67 Max: 7.18
Current: 0.84
0.1
7.18
Earnings Yield (Greenblatt) (%) -0.30
INCY's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. INCY: -0.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INCY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.50 Max: 1.2
Current: -0.3
0.1
1.2

More Statistics

Revenue(Mil) $634
EPS $ -0.50
Beta0.69
Short Percentage of Float3.22%
52-Week Range $64.51 - 133.62
Shares Outstanding(Mil)186.00

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 742 1,051 1,252 1,489
EPS($) -0.20 0.97 1.58 2.16
EPS without NRI($) -0.20 0.97 1.58 2.16

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany,
Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 

More From Other Websites
Despite Target Cuts, Analysts Stick With Incyte for Big Upside Jan 30 2016
A Bad Day for Biotech as Celgene, Incyte Tumble Jan 28 2016
Incyte Halts Phase II Jakafi-Stivarga Combination Study Jan 28 2016
Top Analyst Upgrades and Downgrades: Boeing, eBay, Facebook, Incyte, Kinder Morgan, PayPal,... Jan 28 2016
Technical Roundup on Biotechnology Equities -- Incyte, Juno Therapeutics, Amicus Therapeutics, and... Jan 28 2016
Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with... Jan 27 2016
Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with... Jan 27 2016
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Jan 26 2016
Incyte to Report Fourth Quarter/Year-End Financial Results Jan 21 2016
Incyte to Report Fourth Quarter/Year-End Financial Results Jan 21 2016
Incyte Reports Baricitinib NDA Filing for Rheumatoid Arthritis Jan 20 2016
Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs Jan 20 2016
What Makes Incyte (INCY) a Strong Sell? Jan 20 2016
Coverage initiated on Incyte by Credit Suisse Jan 20 2016
[$$] Eli Lilly Seeks Approval for Rheumatoid-Arthritis Drug Jan 19 2016
Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib... Jan 19 2016
Incyte's stock surges after receiving milestone payment from Eli Lilly Jan 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK